Exeliom Biosciences closes 24 million Series A financing

French clinical-stage developer of immunotherapies Exeliom Biosciences today announced the completion of its 24 million-euro ($26 million) Series A financing to progress the clinical development of its therapeutic pipeline.

This follows on from the initial closing of 7 million euros in 2018, a first extension of 3 million euros in 2021 and the 6 million euros non-dilutive funding secured over the period, the company noted.

Exeliom says it will use the financing proceeds to progress the clinical development of its lead candidate EXL01 into two new therapeutic areas: immuno-oncology and infectious diseases. EXL01 is a once daily, potentially first-in-class, microbiome-based immunotherapy containing a well characterized, unmodified, single-strain of the major dominant commensal bacterium Faecalibacterium prausnitzii.